Evaluation of carbapenem resistance genes in carbapenem-resistant Enterobacteriaceae isolates with GeneXpert® Carba-R panel
DOI:
https://doi.org/10.3855/jidc.22771Keywords:
carbapenem, carbapenemase, Enterobacteriaceae, resistanceAbstract
Introduction: Early detection of increases in carbapenem resistance among Enterobacteriaceae infections due to the widespread use of antibiotics is crucial. This study aimed to identify carbapenemase resistance genes in carbapenem-resistant Enterobacteriaceae isolates using the GeneXpert Carba-R Panel (Cepheid, Sunnyvale, USA).
Methodology: A total of 120 carbapenem-resistant Enterobacteriaceae isolates collected between January and June 2022 at the Microbiology Laboratory of Erzincan Mengücek Gazi Training and Research Hospital were included. The samples were cultured, and then incubated at 37 °C for 24–48 hours. Species-level identification and carbapenem resistance were determined using the VITEK MS and VITEK 2 automated systems (bioMérieux, Marcy l’Étoile, France). Carbapenemase gene detection was performed using the GeneXpert Carba-R assay, and antibiotic susceptibility testing was conducted according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines (version 12.0, 2022) using the VITEK 2 system.
Results: The most common carbapenemase genes detected were blaOXA-48 (65.0%), blaKPC (14.2%), blaNDM (4.2%), and blaVIM (1.7%). Additionally, combinations of resistance genes were observed in 3.3% (blaVIM + blaOXA-48 + blaKPC), 2.5% (blaOXA-48 + blaKPC), and 0.8% (blaVIM + blaKPC) of isolates. Klebsiella pneumoniae was the most frequently isolated species (116). All the isolates were resistant to ertapenem. The most effective antibiotics were colistin, imipenem, amikacin, and trimethoprim-sulfamethoxazole, in descending order of effectiveness.
Conclusions: The findings provide essential insights into alternative treatment options and surveillance of resistance to carbapenem-resistant Enterobacteriaceae. The results may also serve as a reference for future comparative studies and aid in developing effective infection control strategies.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Canan Dizili Yelgin, Barış Gülhan, Halil Yazgı
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
